CN103439485B - Kit for efficiently detecting endogenous digitalis-like factor content and application method thereof - Google Patents
Kit for efficiently detecting endogenous digitalis-like factor content and application method thereof Download PDFInfo
- Publication number
- CN103439485B CN103439485B CN201310371006.5A CN201310371006A CN103439485B CN 103439485 B CN103439485 B CN 103439485B CN 201310371006 A CN201310371006 A CN 201310371006A CN 103439485 B CN103439485 B CN 103439485B
- Authority
- CN
- China
- Prior art keywords
- kit
- edf
- concentration
- unabain
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a kit for efficiently detecting endogenous digitalis-like factor content and an application method thereof. The kit comprises primary antibody goat anti-human digoxin polyclonal antibody, secondary antibody rat anti-goat IgG, 3H labeled uabain, polyethyleneglycol (PEG) 4000, phosphate buffer solution (PBS) with the pH value of 7.4, 3H scintillation solution, and tris(hydroxymethyl)metyl aminomethan buffer solution (Tris buffer solution) with the pH value of 7.4, and/or uabain. The kit provided by the invention is simple and convenient to operate, has the advantages of high sensitivity, high specificity and the like, and can perform stable and reliable early diagnosis on gestational period eclamptism, thereby providing favorable support for subsequent treatment.
Description
Technical field
The invention belongs to and belong to technical field of medical instruments, especially a kind of kit of efficient detection EDF content and using method.
Background technology
Pregnancy period pre-eclampsia (pregnancy period is epilepsy early) is the syndrome that a kind of disease sends out reason complexity, if treated not in time, can develop into eclampsia, threat to life.Cardinal symptom has hypertension, albuminuria, oedema, and faint from fear, renal dysfunction etc., have become a kind of disease that pregnant woman's fatal rate is the highest in the world, at present concrete etiology unknown.There are some researches prove, a kind of material of susceptible women parent blood vessel endothelial dysfunction that causes that placenta produces may be one of them reason that morning, epilepsy disease was sent out.It is that this disease the most significantly indicates that blood pressure raises, and causes puerpera's endothelium, the infringement of kidney and liver simultaneously.
In global pregnant woman, the incidence of disease is 6-8% to pre-eclampsia (early epilepsy), is usually fallen ill in late period gestation second phase or pregnant three phases, and major part is in the sequela (before 32 weeks, morbidity is considered to early stage morbidity) in 32 weeks pregnancy periods, and only a few pregnant woman can fall ill 20 weeks pregnancy periods.Pregnant woman's incidence of disease of Primiparous time-pregnant is the highest, and along with the increase of number of pregnancies, this disease incidence significantly reduces.Early epilepsy is mainly in and has history of hypertension, diabetic history, obesity history, and autoimmune disease history is as lupus, and in the pregnant woman of multifetation (twins or multiparity), its pathogenic process varies with each individual, and most of case can be made a definite diagnosis before childbirth.Minority case was just made a definite diagnosis in point six weeks puerperiums, was called " postpartum is epilepsy early ", except caesarean birth or induced labor operation after making a definite diagnosis, did not have other treatment mode.Early epilepsy is modal pregnancy syndrome, affects mother and fetus simultaneously, causes premature even to cause life danger to mother and baby.
Traditionally early epilepsy make a definite diagnosis mark be pregnancy period hypertension (two measured values of being independently at least separated by six hours, systolic pressure be more than 140 and/or diastolic pressure be more than 90) and twenty-four-hour urine fluid samples in protein content higher than 300 milligrams (albuminuria).Than the systolic pressure of high 30 mm Hg of baseline blood pressure (BP) or the diastolic pressure of high 15 mm Hg, the absolute standard of 140/90 can not be reached, be still considered to important morbidity signal, but can not make a definite diagnosis at this point.Swelling or oedema (especially at hand and face) were once considered to the important symbol diagnosing early epilepsy at first, but current medical practice proves, only had HP can as diagnostic criteria.
Although early epilepsy is a kind of fatal disease, but its morbidity is in early days usually asymptomatic, and generally, early the signal of epilepsy is not specific, the such as pregnancy period faints from fear, in pregnancy, cause easier than eclampsia of other reasons faints from fear, and therefore early the early diagnosis of epilepsy is the difficult problem that medical circle cannot be captured always.
In the symptom of epilepsy patient morning, a kind of rising of sodium potassium pump inhibiting factor-EDF (endogenousdigitalis-likefactor, EDLF) level is the important symbol of early epilepsy.This factor can cause blood pressure to raise, be present in human body and animal tissue and body fluid, its chemical constitution is similar to the steroids cardiotonic extracted in plant digitalis with biologically active, therefore named " digitalis-like factor ", this factor can be attached on sodium potassium pump with the mechanism similar with cardiotonics such as digoxin, and suppress it active, but so far, the particular chemical of this type of factor is still unknown.Many hypertensions all find the rising with EDF level, and therefore, this factor is likely and causes hypertensive reason.
Research shows, DigiTAb can reverse the sodium potassium pump inhibiting factor of plant origin and the effect of EDF, particularly a kind of once for digoxin excess intake treatment, the digoxin antibody fragment specifically of Digibind by name, this antibody can be combined with EDF and suppress it to act on, and reduces blood pressure.In the clinical randomized double-blind experiment of epilepsy women morning, the women's blood pressure accepting DigiTAb treatment obviously reduces than placebo group, renal dysfunction also has and significantly improves, these evidences further demonstrate the effect of EDF in the morning epilepsy origin cause of formation, DigiTAb, by being combined with this factor, plays the effect alleviating illness.
In order to realize the early diagnosis to pregnancy early epilepsy, reaching the object of early treatment, needing using DigiTAb as instrument, develop and a kind ofly specificity can accurately measure the method for EDF in sample, and make kit simple and efficient to handle.In decades after this factor is found, the greatest difficulty of research is, its content is in vivo very low, and is not also determined also do not have method its () can be separated in body at present due to structure.Therefore, the kit in the present invention provides one and does not need clinically to be isolated, but still can this factor concentration of sensitive determination, and as the foundation of early epilepsy early diagnosis.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, a kind of kit and using method of simple to operation, highly sensitive, high specificity, reliable and stable efficient detection EDF content are provided, the detection of this kit can reach nM and nanomole/liter, for successive treatment provides favourable support.
The technical scheme that the present invention realizes object is as follows:
Detect a kit for EDF content, comprise following component
Primary antibodie goat-anti people digoxin polyclonal antibody, the anti-sheep IgG of two against murine,
3h mark unabain, Macrogol 4000, pH=7.4 phosphate buffer,
3the Tris damping fluid of H scintillation solution, pH=7.4.
And, also comprise unabain.
And, described primary antibodie goat-anti people digoxin Anti-TNF-α bulk concentration 12 mcg/ml, described two against murine anti-sheep IgG concentration 5 × 10
-7mol/L, it is 10.0Ci/mmol that described 3H marks unabain concentration, and described Macrogol 4000 concentration is 30wt%.
And described kit is used for the content of the EDF in human body serum, placenta tissue juice and freezing placenta tissue.
A kit using method for detection EDF content as claimed in claim 1, step is as follows
(1) gather placenta, be cut into tissue block, liquid nitrogen frozen, be stored in-80 DEG C;
(2) freezing placenta tissue block is thinly sliced, be placed in homogenizer, put into liquid nitrogen container freezing 1 minute; With the speed of 1500rpm by tissue slice homogenate 5 minutes;
(3) collect homogenised tissue, add the methyl alcohol of equivalent, mixing, with the centrifugation 5 minutes of 2000rpm, remove albumen; Collect centrifuged supernatant, Vacuum Concentration, 4 DEG C of preservations;
(4) take out goat-anti people digoxin polyclonal antibody in kit, the anti-sheep IgG of two against murine,
3h marks the TRIS buffer of unabain, pH=7.4, and equivalent adds respectively, fully mixes, incubated at room with equivalent testing sample;
(5) add the PEG4000 solution of equivalent again, centrifugal 10 minutes of 8000rpm, is precipitated thing;
(6) sediment is resuspended with the PBS of 500 microlitre pH7.4, adds
3h scintillation solution;
(7) measure sample exit dose, calculate contained EDF concentration in sample according to typical curve.
Advantage of the present invention and good effect are:
1, the invention provides and a kind ofly detect quick, simple to operation, that high specificity, good stability and sensitivity are high kit, effectively can detect the content of EDF in sample, solve for a long time to morning epilepsy early diagnosis research significant difficulties.
2, this kit may be used for the concentration measuring EDF in placenta and blood serum sample, for laying good basis to the research of synthesizing adjustment in the mechanism of causing a disease of this factor, body further, and the pathological study work of pregnancy period early epilepsy is made to have striden forward major step.
Accompanying drawing explanation
Fig. 1 is that DigiTAb of the present invention reverses the inhibiting effect of EDF to sodium potassium pump in morning epilepsy, and ordinate represents the repressed number percent of sodium potassium pump in erythrocyte, unit %; A representative contrast in figure, B representative does not use epilepsy clinical samples morning of DigiTAb, and C representative uses epilepsy clinical samples morning after DigiTAb.
Fig. 2 is typical curve of the present invention (obtaining according to Specification Curve of Increasing method), and horizontal ordinate represents the log(mol/L of unabain solution concentration) value; Ordinate is radioactivity, and ordinate represents the contamination that standard unabain solution records through the method for the invention, y=0.0671e
-1.4038x, R
2=0.9979.
Fig. 3 is the concentration of the EDF secreted in the ten a independent placental samples measured of kit of the present invention, and sample is from normal pregnancies, and wherein, horizontal ordinate 1-11 represents ten a independent samples respectively; Ordinate represents EDF concentration, unit receive rub/liter.
Fig. 4 be kit of the present invention for determining the concentration of EDF in placenta tissue, sample is from epilepsy pregnant woman morning, and wherein, horizontal ordinate 1-5 represents 5 parts of independent samples respectively; Ordinate represents EDF concentration, unit receive rub/liter.
Fig. 5 is kit of the present invention for measuring the concentration of EDF in early epilepsy pregnancy serum, and wherein, horizontal ordinate 1-7 represents 7 parts of independent samples respectively; Ordinate represents EDF concentration, unit receive rub/liter.
Fig. 6 is EDF concentration accumulation in time in invention kits Human plactnta of the present invention, and wherein, horizontal ordinate represents incubation time, unit hour; Ordinate represents EDF concentration, unit 10
-8rub/liter.
Fig. 7 is the comparison that GFAA method (Graphite Furnance Atomic Absorption Spectrometry, GFAAS (graphite furnace atomic absorption spectrometry)) and kit method therefor of the present invention detect EDF in identical Placenta samples.Horizontal ordinate represents the percent activity that GFAA method records this factor in sample, unit %; Factor content in the sample that ordinate representative uses kit of the present invention to record, unit: Na Mo/liter
Embodiment
Below by specific embodiment, the invention will be further described, and following examples are descriptive, is not determinate, can not limit protection scope of the present invention with this.
Goat-anti people digoxin polyclonal antibody (anti digoxin antibody) of the present invention has another name called anti digoxin antibody purchased from GlaxoSmithKline(), the anti-sheep IgG of two against murine all purchased from Jackson ImmunoResearchLaboratories, Inc,
3h mark unabain purchased from PerkinElmer, Macrogol 4000 purchased from Calbiochem, pH=7.4 phosphate buffer (PBS damping fluid) autogamy,
3h scintillation solution purchased from NationalDiagnostics, unabain purchased from the TRIS buffer (Tris damping fluid) of Sigma, pH=7.4 purchased from Sigma, DMEM nutrient solution purchased from Gibson.
This kit composed as follows:
Goat-anti people digoxin polyclonal antibody 12 mcg/ml, two anti-sheep IgG5 × 10 of against murine
-7mol/L,
3the phosphate buffer (PBS damping fluid) that H mark unabain concentration is 10.0Ci/mmol, Macrogol 4000 concentration is 30wt%, pH=7.4,
3the Tris damping fluid of H scintillation solution, unabain, pH=7.4.
Kit of the present invention needs to measure
3the radioactive instrument and equipment of H is measured.(equipment is called scintillationcounter.Any laboratory of doing radioactivity experiment has, and operating process is for put in sample, and operation software, directly goes out result.）
Embodiment 1:
Kit is for measuring the EDF content of placenta tissue secretion
(1) gather the Freshman placenta that delivery time is less than 6 hours;
(2) push amnion aside, get the tissue block 4-5 block of 5mmX5mmX5mm size, put into PBS and wash remained blood off;
(3) tissue block is cut into particulate, removes the visible clot of naked eyes and blood vessel, be washed till without blood residuals with PBS, aseptic filter paper blots PBS, put into DMEM nutrient solution, 37 DEG C, 5%CO
2cultivate 48 hours;
(4) collect nutrient solution, centrifugal segregation residual tissue block, 4 DEG C of preservations;
(5) take out goat-anti people digoxin polyclonal antibody in kit, the anti-sheep IgG of two against murine,
3h marks unabain, gets 100 microlitres respectively, fully mixes, incubated at room with 100 microlitre testing samples;
(6) add 400 microlitre PEG4000 solution again, centrifugal 10 minutes of 8000rpm, is precipitated thing;
(7) sediment is resuspended with the PBS of 500 microlitre pH7.4, adds 4 milliliters
3h scintillation solution;
(8) measure sample exit dose, calculate contained EDF concentration in sample according to typical curve.
Result as shown in Figure 3, the EDF concentration utilizing this kits to go out to secrete in independent placenta tissue, unit rubs for receiving/liter, this concentration accurately can be measured by kit provided by the invention.
Embodiment 2:
This kit is for measuring the content of EDF in cryonics placenta tissue
(1) gather neonate's placenta, be cut into the tissue block of 2cm × 2cm × 2cm size, liquid nitrogen frozen, is stored in-80 DEG C;
(2) freezing placenta tissue block is thinly sliced, be placed in homogenizer, put into liquid nitrogen container freezing 1 minute; With the speed of 1500rpm by tissue slice homogenate 5 minutes;
(3) collect homogenised tissue, add 5 ml methanol, mixing, with the centrifugation 5 minutes of 2000rpm, remove albumen; Collect centrifuged supernatant, Vacuum Concentration, 4 DEG C of preservations;
Measure sample method with step in embodiment 1 (5)-(8).
As shown in Figure 4, this kit can measure the concentration of EDF in freezing placenta tissue, 100 times in average out to embodiment 1, and sample source is all diagnosed as the sick originator of early epilepsy.
Embodiment 3:
This kit is for measuring the content of EDF in human serum
Measure sample method with step in embodiment 1 (5)-(8).
As shown in Figure 5, this kit can accurately measure the EDF of low content in human serum to result.
In pregnancy serum EDF concentration receive more than 150 rub/liter, tentatively can be judged as early epilepsy patient.
Refer to EDF content in pregnancy serum herein, because hospital is before pregnant woman childbirth, chemical examination serum is most convenient.But because this factor produces in placenta, placenta content will far away higher than serum content, as Fig. 4 and Fig. 5 contrast; And for example Fig. 3, display normal pregnancies placenta secretion is to the factor concentration in nutrient solution, with factor concentration tool comparability in the serum of early epilepsy patient in Fig. 5, further demonstrate that in serum, content is far less than placenta, the low content of this factor in serum, and chemical examination serum is more convenient than placenta, is important innovations of the present invention.
Embodiment 4:
This kit secretes the accumulation of EDF for measuring in human placenta, method is with embodiment 1.
As shown in Figure 6, along with the accumulation of tissue cultures time, the EDF content that this kit measures Human plactnta secretion progressively increases.
Specification Curve of Increasing step is as follows:
(1) get concentration be respectively 50 receive rub/liter, 0.1 micro-ly to rub/liter, 0.2 micro-ly to rub/liter, 0.5 micro-ly to rub/liter, 1 micro-ly to rub/liter, 3 micro-ly to rub/liter each 100 microlitres of unabain solution;
(2) take out the Tris damping fluid of goat-anti people digoxin polyclonal antibody, two against murine anti-sheep IgG, pH=7.4 in kit, add 100 microlitres respectively in the unabain solution of above-mentioned variable concentrations, fully mix, incubated at room;
(3) add 400 microlitre PEG4000 solution again, centrifugal 10 minutes of 8000rpm, is precipitated thing;
(4) sediment is resuspended with the PBS of 500 microlitre pH7.4, adds 3H scintillation solution;
(5) measure sample exit dose, obtain contained EDF concentration in sample, curve plotting, obtains typical curve.
Because unabain can be attached on anti digoxin antibody with the Percentage bound identical with EDF, the concentration of EDF in the concentration representative sample of known unabain standard solution can be utilized.
The measurement factor content method of Fig. 7 is with embodiment 1, namely get placenta tissue nutrient solution and measure exit dose, result shows concentration and its activity being linear relation of EDF in placenta tissue, the reliability of detection method described in further proved invention.
Claims (4)
1. detect a kit for EDF content, it is characterized in that: comprise following component
Primary antibodie goat-anti people digoxin polyclonal antibody, the anti-sheep IgG of two against murine,
3h mark unabain, Macrogol 4000, pH=7.4 phosphate buffer,
3the Tris damping fluid of H scintillation solution, pH=7.4.
2. the kit of detection EDF content according to claim 1, is characterized in that: also comprise unabain.
3. the kit of detection EDF content according to claim 1, is characterized in that: described primary antibodie goat-anti people digoxin Anti-TNF-α bulk concentration 12 mcg/ml, described two against murine anti-sheep IgG concentration 5 × 10
-7mol/L, described in
3it is 10.0Ci/mmol that H marks unabain concentration, and described Macrogol 4000 concentration is 30wt%.
4. the kit using method detecting EDF content as claimed in claim 1, is characterized in that: step is as follows
(1) gather placenta, chopping, liquid nitrogen frozen, is stored in-80 DEG C;
(2) freezing placenta tissue block is thinly sliced, be placed in homogenizer, put into liquid nitrogen container freezing 1 minute; With the speed of 1500rpm by tissue slice homogenate 5 minutes;
(3) collect homogenised tissue, add the methyl alcohol of equivalent, mixing, centrifugal segregation albumen; Collect centrifuged supernatant, Vacuum Concentration, 4 DEG C of preservations;
(4) take out goat-anti people digoxin polyclonal antibody in kit, the anti-sheep IgG of two against murine,
3h marks the TRIS buffer of unabain, pH=7.4, and equivalent adds respectively, fully mixes, incubated at room with equivalent testing sample;
(5) add the PEG4000 solution of equivalent again, centrifugal, be precipitated thing;
(6) sediment is resuspended with the PBS of 500 microlitre pH7.4, adds
3h scintillation solution;
(7) measure sample exit dose, calculate the concentration of contained EDF in sample according to typical curve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310371006.5A CN103439485B (en) | 2013-08-22 | 2013-08-22 | Kit for efficiently detecting endogenous digitalis-like factor content and application method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310371006.5A CN103439485B (en) | 2013-08-22 | 2013-08-22 | Kit for efficiently detecting endogenous digitalis-like factor content and application method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103439485A CN103439485A (en) | 2013-12-11 |
| CN103439485B true CN103439485B (en) | 2015-01-21 |
Family
ID=49693189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310371006.5A Active CN103439485B (en) | 2013-08-22 | 2013-08-22 | Kit for efficiently detecting endogenous digitalis-like factor content and application method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103439485B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103439507B (en) * | 2013-08-22 | 2015-03-25 | 天津市康婷生物工程有限公司 | Kit for detecting endogenous digitalis-like factor content with digoxin monoclonal antibody and application method thereof |
| CN105435617B (en) * | 2015-11-19 | 2018-06-19 | 史汉祥 | For the equipment of flue gas desulfuration and denitrification |
| CN113736744B (en) * | 2021-10-14 | 2023-07-18 | 江南大学 | Digitoxin monoclonal antibody hybridoma cell strain and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975511A (en) * | 1974-03-01 | 1976-08-17 | Corning Glass Works | Solid phase radioimmunoassay |
| EP0433074A1 (en) * | 1989-12-13 | 1991-06-19 | The General Hospital Corporation | Method for treating cardiac malfunction |
| CN1688337A (en) * | 2002-07-25 | 2005-10-26 | 查尔斯·戴维·阿代尔 | Use of digoxin immune FAB (ovine) for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5728494A (en) * | 1992-12-02 | 1994-06-22 | Alexei Y. Bagrov | Anti-edlf antibody, composition thereof and method of diagnosing and treating cardiac arrhythmias, hypertension |
-
2013
- 2013-08-22 CN CN201310371006.5A patent/CN103439485B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975511A (en) * | 1974-03-01 | 1976-08-17 | Corning Glass Works | Solid phase radioimmunoassay |
| EP0433074A1 (en) * | 1989-12-13 | 1991-06-19 | The General Hospital Corporation | Method for treating cardiac malfunction |
| CN1688337A (en) * | 2002-07-25 | 2005-10-26 | 查尔斯·戴维·阿代尔 | Use of digoxin immune FAB (ovine) for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
Non-Patent Citations (2)
| Title |
|---|
| Correlation between endogenous digoxin-like immunoreactivity and 3H-ouabain displacement on erythrocyte membranes in extract;Silvana Balzan et al;《Clinical Biochemistry》;19861031;第19卷(第5期);第311-314页 * |
| 冠心病患者血清内源性洋地黄因子的放免测定与意义;柯永胜等;《心血管学报》;19910228;第10卷(第2期);第103-104页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103439485A (en) | 2013-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bouachba et al. | Placental lesions and SARS-Cov-2 infection: diffuse placenta damage associated to poor fetal outcome | |
| Carroll et al. | A specific laboratory test for the diagnosis of melancholia: standardization, validation, and clinical utility | |
| Terpos et al. | Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration | |
| Sater et al. | Anti-phosphatidylserine, anti-cardiolipin, anti-β2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8–12 gestational weeks | |
| Huang et al. | Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy | |
| Dubucs et al. | Severe placental lesions due to maternal SARS-CoV-2 infection associated to intrauterine fetal death | |
| Brubel et al. | Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders | |
| CN103439485B (en) | Kit for efficiently detecting endogenous digitalis-like factor content and application method thereof | |
| Kawaguchi et al. | Changes in d-dimer levels in pregnant women according to gestational week | |
| JP5677294B2 (en) | Test method for kidney disease | |
| CN103439492B (en) | Kit | |
| CN103439507B (en) | Kit for detecting endogenous digitalis-like factor content with digoxin monoclonal antibody and application method thereof | |
| Kase et al. | Elevation of serum Krebs von den Lunge–6 levels in patients with tubulointerstitial nephritis and uveitis syndrome | |
| Mawlood et al. | Evaluation of invasive and non-invasive methods for the diagnosis of H. pylori in dyspepsia patients | |
| CN103207274A (en) | Screening kit for seventh chromosome abnormality diseases of fetus | |
| Kamimoto et al. | High frequency of decreased antithrombin level in pregnant women with thrombosis | |
| Hedner et al. | Fibrinolytic split products in serum and urine in pregnancy | |
| Adam et al. | Influence of oral contraceptives and pregnancy on constituents of the kallikrein-kininogen system in plasma. | |
| Yao et al. | Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction | |
| Zayed et al. | Assessment of hepatic fibrosis by fibroscan in egyptian chronic hemodialysis patients with chronic Hepatitis C (genotype 4): A single-center study | |
| Karahan et al. | Serum anti-carbonic anhydrase I and II antibodies and idiopathic recurrent pregnancy loss | |
| Akhter et al. | Dimethylarginines correlate to common carotid artery wall layer dimensions and cardiovascular risk factors in pregnant women with/without preeclampsia: A group comparative study | |
| Abed et al. | Correlation between Neutrophil Gelatinase Associated with Lipocaline and Beta-2 Microglobulin with Other Renal Markers in Iraqi Patients with Multiple Myeloma | |
| CN105158454A (en) | Kit and detection method thereof | |
| Draj et al. | Serum Levels of Glycodelin A and Soluble Intracellular Adhesion Molecule-1 as Biomarkers for Endometriosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: No.9 Saida South Road, Xiqing Economic and Technological Development Zone, Tianjin 300200 Patentee after: Tianjin Kangting Bioengineering Group Co., Ltd. Address before: No. 126 Youyi South Road, Saida Pharmaceutical Industrial Park, Xiqing Economic and Technological Development Zone, Tianjin 300200 Patentee before: Tianjin Kangting Biotechnology Co., Ltd. |
|
| CP03 | Change of name, title or address |